NASDAQ: MDXG
Mimedx Group Inc Stock Forecast, Predictions & Price Target

Analyst price target for MDXG

Based on 2 analysts offering 12 month price targets for Mimedx Group Inc

Min Forecast
$11.00+20.61%
Avg Forecast
$11.50+26.1%
Max Forecast
$12.00+31.58%

Should I buy or sell MDXG stock?

Based on 2 analysts offering ratings for Mimedx Group Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their MDXG stock forecasts and price targets.

MDXG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-01
lockedlocked$00.00+00.00%2024-08-01

1 of 1

Forecast return on equity

Is MDXG forecast to generate an efficient return?

Company
N/A
Industry
229.92%
Market
67.05%

Forecast return on assets

Is MDXG forecast to generate an efficient return on assets?

Company
N/A
Industry
35.19%

MDXG earnings per share forecast

What is MDXG's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$0.30-52.38%
Avg 2 year Forecast
$0.42-33.33%
MDXG's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

MDXG revenue forecast

What is MDXG's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$375.0M+9.39%
Avg 2 year Forecast
$430.0M+25.44%
MDXG's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MDXG earnings growth forecast

How is MDXG forecast to perform vs Biotechnology companies and vs the US market?

Company
3.9%
Industry
14.76%
Market
19.98%
MDXG's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
MDXG's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
MDXG's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

MDXG revenue growth forecast

How is MDXG forecast to perform vs Biotechnology companies and vs the US market?

Company
12.98%
Industry
50.29%
Market
11.63%
MDXG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MDXG's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MDXG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MDXG$9.12$11.50+26.10%Strong Buy
KNSA$18.54$37.25+100.92%Strong Buy
NVAX$8.40$19.75+135.12%Buy
XNCR$19.24$32.60+69.44%Strong Buy
NRIX$19.14$33.30+73.98%Strong Buy

Mimedx Group Stock Forecast FAQ

Is Mimedx Group Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: MDXG) stock is to Strong Buy MDXG stock.

Out of 2 analysts, 1 (50%) are recommending MDXG as a Strong Buy, 1 (50%) are recommending MDXG as a Buy, 0 (0%) are recommending MDXG as a Hold, 0 (0%) are recommending MDXG as a Sell, and 0 (0%) are recommending MDXG as a Strong Sell.

If you're new to stock investing, here's how to buy Mimedx Group stock.

What is MDXG's earnings growth forecast for 2025-2026?

(NASDAQ: MDXG) Mimedx Group's forecast annual earnings growth rate of 3.9% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.98%.

Mimedx Group's earnings in 2025 is $93,642,000.On average, 1 Wall Street analyst forecast MDXG's earnings for 2025 to be $44,083,864, with the lowest MDXG earnings forecast at $44,083,864, and the highest MDXG earnings forecast at $44,083,864.

In 2026, MDXG is forecast to generate $61,717,409 in earnings, with the lowest earnings forecast at $61,717,409 and the highest earnings forecast at $61,717,409.

What is MDXG's revenue growth forecast for 2025-2026?

(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 12.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.29%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.63%.

Mimedx Group's revenue in 2025 is $342,805,000.On average, 1 Wall Street analysts forecast MDXG's revenue for 2025 to be $55,104,829,875, with the lowest MDXG revenue forecast at $55,104,829,875, and the highest MDXG revenue forecast at $55,104,829,875.

In 2026, MDXG is forecast to generate $63,186,871,590 in revenue, with the lowest revenue forecast at $63,186,871,590 and the highest revenue forecast at $63,186,871,590.

What is MDXG's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MDXG) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.19%.

What is MDXG's Price Target?

According to 2 Wall Street analysts that have issued a 1 year MDXG price target, the average MDXG price target is $11.50, with the highest MDXG stock price forecast at $12.00 and the lowest MDXG stock price forecast at $11.00.

On average, Wall Street analysts predict that Mimedx Group's share price could reach $11.50 by Aug 1, 2025. The average Mimedx Group stock price prediction forecasts a potential upside of 26.1% from the current MDXG share price of $9.12.

What is MDXG's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: MDXG) Mimedx Group's current Earnings Per Share (EPS) is $0.63. On average, analysts forecast that MDXG's EPS will be $0.30 for 2025, with the lowest EPS forecast at $0.30, and the highest EPS forecast at $0.30. In 2026, MDXG's EPS is forecast to hit $0.42 (min: $0.42, max: $0.42).

What is MDXG's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MDXG) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.